Northern Trust Corp Takes $1.24 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Northern Trust Corp acquired a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 64,044 shares of the company's stock, valued at approximately $1,242,000. Northern Trust Corp owned 0.18% of Oruka Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at $144,000. AlphaCentric Advisors LLC bought a new stake in Oruka Therapeutics in the fourth quarter valued at about $119,000. Charles Schwab Investment Management Inc. acquired a new position in Oruka Therapeutics in the fourth quarter valued at about $303,000. Vanguard Group Inc. lifted its stake in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after buying an additional 1,572,853 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in Oruka Therapeutics during the fourth quarter worth about $54,000. 56.44% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ORKA has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Wolfe Research began coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 target price for the company. BTIG Research initiated coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They issued a "buy" rating on the stock. HC Wainwright reissued a "buy" rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, February 7th. Finally, Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 15th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Oruka Therapeutics has a consensus rating of "Buy" and an average price target of $40.38.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock traded down $0.81 during midday trading on Friday, reaching $11.04. The stock had a trading volume of 327,851 shares, compared to its average volume of 225,192. The stock has a market capitalization of $413.35 million, a P/E ratio of -1.76 and a beta of 0.25. The firm's fifty day simple moving average is $9.74 and its 200-day simple moving average is $13.87. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. On average, sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.